Document Detail

Short-course fluoroquinolones in acute exacerbations of chronic bronchitis.
MedLine Citation:
PMID:  20923343     Owner:  NLM     Status:  MEDLINE    
It is estimated that 50-70% of acute exacerbations of chronic bronchitis (AECB) are caused by bacterial infections. Appropriate selection of antimicrobials may lead to better outcomes and reduced healthcare costs. Respiratory fluoroquinolones (moxifloxacin, levofloxacin and gemifloxacin) have a broad spectrum of activity against most AECB-causing pathogens and are used as first-line treatment in patients with comorbidity, severe airway obstruction or recurrent exacerbations. We review studies, identified through a MEDLINE search, that compared clinical efficacy and speed of recovery for short-course (≤ 5 days) fluoroquinolone therapy with commonly prescribed standard therapy (≥ 7 days). Among 177 studies reporting the use of fluoroquinolones for AECB treatment, 23 used a short-course regimen, shown to be at least as effective as standard therapy of 7 or more days duration. Furthermore, evidence suggests that short-course therapy offers faster resolution of symptoms, faster rate of recovery, fewer relapses, fewer and shorter hospitalizations, and longer time between recurrences.
Mark H Gotfried; Ronald F Grossman
Related Documents :
23836813 - An analysis of the use of the kellgren and lawrence grading system to evaluate peritala...
23851923 - Bony periosteum-covered iliac crest plug transplantation for severe osteochondral lesio...
11397623 - Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert review of respiratory medicine     Volume:  4     ISSN:  1747-6356     ISO Abbreviation:  Expert Rev Respir Med     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-06     Completed Date:  2011-01-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101278196     Medline TA:  Expert Rev Respir Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  661-72     Citation Subset:  IM    
College of Medicine, University of Arizona, 1112 East McDowell Road, Phoenix, AZ 85006, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Airway Obstruction / drug therapy,  microbiology
Anti-Bacterial Agents / administration & dosage*
Bronchitis, Chronic / drug therapy*,  microbiology
Drug Administration Schedule
Fluoroquinolones / administration & dosage*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Fluoroquinolones

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lung epithelial wound healing in health and disease.
Next Document:  Monitoring chronic cough: current and future techniques.